LAIR1 and lung cancer: Lastly, our pre-clinical and clinical findings emphasize the need to develop specific inhibitors of LAIR1 to synergize with PD-1/PD-L1 blockade therapies and emphasize the need to have greater accessibility to lung cancer patient datasets with pre- and post-treatment samples.